Candesartan
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Candesartan: From Hypertension to Migraine Disorder
One-Sentence Summary
Candesartan is an angiotensin II type 1 receptor blocker (ARB), a class normally used for hypertension. The SAHPRA indication text was not supplied in the data. The TxGNN model predicts it may be effective for migraine disorder (preventive treatment). Support comes from 3 directly relevant clinical trials (including a completed Phase 2 RCT with 450 patients) and 20 publications, including a 2025 Lancet Neurology RCT.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (general pharmacology of the ARB class; SAHPRA indication text not supplied) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank. Based on known pharmacology, candesartan is an AT1 receptor blocker. It is proven in cardiovascular disease, and mechanistically it may be applicable to migraine prevention.
Proposed mechanisms include modulation of cerebrovascular tone, neurovascular inflammation and trigeminovascular signalling through the renin-angiotensin system. These are hypotheses, not established facts.
Clinical support is stronger than for most TxGNN predictions. A completed, triple-blind, placebo-controlled Phase 2 RCT (n=450) and a smaller Phase 2/3 comparison against propranolol (n=72) both address migraine prevention directly. No adequately powered Phase 3 trial is present, so the evidence level is capped at L2.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04574713 | Phase 2 | Completed | 450 | Multicentre, triple-blind, placebo-controlled trial of candesartan 8 mg and 16 mg for episodic migraine prevention. It tests whether earlier small-study benefit is confirmed and also assesses tolerability. |
| NCT00884663 | Phase 2/3 | Completed | 72 | Double-blind, double-dummy triple cross-over comparing candesartan, propranolol and placebo for migraine prophylaxis. Direct evidence, but small. |
| NCT04138316 | N/A (observational) | Completed | 85 | CandeSpartan study: real-world response predictors and tolerability in migraine after failure of 3 or more preventive drugs. It informs tolerability, not efficacy. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40975098 | 2025 | RCT (Phase 2) | Lancet Neurol | Triple-blind, placebo-controlled trial of candesartan for episodic migraine prevention, evaluating safety, tolerability and efficacy. |
| 37350141 | 2023 | Systematic review / meta-analysis | Cephalalgia | Assesses whether blood-pressure-lowering drugs beyond the few currently recommended prevent episodic migraine. |
| 38057728 | 2023 | Systematic review / network meta-analysis | J Headache Pain | Ranks preventive drugs for chronic migraine in adults. |
| 39899861 | 2025 | Guideline | Ann Intern Med | American College of Physicians guideline on pharmacologic prevention of episodic migraine in outpatients. |
| 38663908 | 2024 | Cohort | Cephalalgia | CandeSpartan: effectiveness, tolerability and response predictors of candesartan in clinical practice. |
| 33589682 | 2021 | Retrospective cohort | Sci Rep | Real-world effectiveness and tolerability of candesartan in migraine. It notes that only two RCTs supported use before this work. |
| 40571531 | 2025 | Scoping review | Clin Ther | Reviews candesartan as a potential migraine treatment. |
| 38307673 | 2024 | Review | Handb Clin Neurol | Lists candesartan among non-specific oral agents for migraine prevention. |
| 22529202 | 2012 | Guideline | Neurology | AAN/AHS evidence-based guideline on migraine prevention. This is an older guideline and predates the recent candesartan trials. |
| 22683887 | 2012 | Guideline | Can J Neurol Sci | Canadian Headache Society guideline on migraine prophylaxis. This is an older guideline. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 48/7.1.3/0472 | Ranepres 8 Mg | Tablet (oral) | Not provided in the data; refer to the PI |
| Reg. No. 48/7.1.3/0514 | Ranepres Plus 16/12.5 Mg | Tablet (oral) | Not provided in the data; refer to the PI |
Ranepres Plus 16/12.5 mg is a fixed-dose combination. The 12.5 mg component is presumably hydrochlorothiazide, and the migraine evidence relates to candesartan alone. The 8 mg and 16 mg trial doses correspond to the 8 mg product and the candesartan component of the combination. No indication text or Essential Medicines List status was supplied.
Safety Considerations
- Drug Interactions: The interaction query returned no results, which means “not found”, not “no interactions”.
- Guardrails from the evidence pack:
- Pregnancy: ARBs are fetotoxic (case reports and reviews describe oligohydramnios, pulmonary hypoplasia and renal damage; e.g. PMID 15669052). Women of childbearing potential need contraception counselling.
- Blood pressure: Watch for hypotension in normotensive migraine patients.
- Monitoring: Renal function and potassium.
Please refer to the SAHPRA-approved Professional Information (PI) for full warnings and contraindications. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed placebo-controlled Phase 2 RCT (n=450), a Phase 2/3 active-comparator trial and supportive real-world cohorts point to a real signal in migraine prevention. The drug is already marketed in South Africa. However, there is no adequately powered Phase 3 trial, and the SAHPRA safety information is missing.
To proceed, the following is needed:
- Extract warnings and contraindications from the SAHPRA package insert (a blocking gap for safety screening).
- Confirm the approved indication text for both registered products.
- Review the full results of NCT04574713 / PMID 40975098 (effect size and adverse events) and confirm the 8 mg and 16 mg doses against locally available strengths.
- Define a monitoring plan covering blood pressure, renal function, potassium and pregnancy prevention.
- Obtain mechanism-of-action data from DrugBank.
Other predictions: The other nine predicted indications (migraine with brainstem aura, migraine susceptibility, pulmonary hypertension, Prinzmetal angina, kyphoscoliotic heart disease, atrophoderma vermiculata, ulerythema ophryogenesis, benign prostatic hyperplasia and alopecia) are not supported by candesartan-specific clinical evidence. They should stay on Hold or be treated as research questions. The migraine susceptibility entry should be merged with the main migraine entry.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.